Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747318 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
A Phase 3 study of Asthma, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT00747318: Completed Phase 3 study of Asthma, sponsored by SkyePharma.
NCT00747318 is a Phase 3 study of Asthma that has completed, run by SkyePharma. The registered enrollment target is 280 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00747318, a Phase 3 study of Asthma, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
Conditions Studied
Interventions
- DRUG SKP FlutiForm HFA pMDI
Study Locations (20)
Lima Province
- Investigational site - Lima
- Investigational site - Lima
- Investigational site - Lima
- Investigational site - Lima
- Investigational site - Lima
Oregon
- Investigational Site - Medford
- Investigational Site - Portland
Rhode Island
- Investigational Site - East Providence
- Investigational Site - Providence
Arizona
- Investigational Site - Scottsdale
California
- Investigational Site - Orange County
Colorado
- Investigational Site - Colorado Springs
Florida
- Investigational Site - Valrico
North Carolina
- Investigational Site - Elizabeth City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00747318 record still lists
NCT00747318 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which SKP FlutiForm HFA pMDI is the first listed.
NCT00747318 names 20 study sites across 14 states, led by Lima Province, Oregon, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00747318 about?
NCT00747318 is a clinical study titled "A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005". The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
What is the current status of trial NCT00747318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2008-09. Estimated completion is 2010-06.
What conditions does trial NCT00747318 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00747318?
The interventions under investigation include: SKP FlutiForm HFA pMDI (DRUG).
Who is sponsoring clinical trial NCT00747318?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747318 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00747318's enrollment target sits among peer trials
280 133rd of 374 higher than 241 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia